SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Boston Scientific (BSX) Any Comments???
BSX 100.55+0.2%Oct 30 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lighthouse who wrote (791)8/3/2002 4:42:33 AM
From: DAGOBERT  Read Replies (1) of 798
 
GDT has an advantage now over BSX. In getting the
Cook business, there is an added value to GDT ,as Cook
has been strong in radiology and particularly interventional
GDT will be dominating in the health care market with their
cardiology lines, particularly electro. physiology .
It looks that the paclitaxel item has also been solved in
GDT's advantage. So, besides the present volatility in the
stockmarket, I believe on the long run one is doing fine
with these shares in GDT.
I wonder what GDT shall be doing with all the Cook companies in the different health sectors?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News